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99BACKGROUND: Antibiotic combinations that include macrolides have shown lower mortality
rates than b-lactams in monotherapy or combined with ﬂuoroquinolones in patients with
community-acquired pneumonia (CAP). However, this effect has not been studied according
to the levels of C-reactive protein in CAP with identiﬁed microbial cause. In patients with
CAP and known microbial cause we aimed to evaluate 30-day mortality of a b-lactam plus
macrolide (BL þ M) compared with a ﬂuoroquinolone alone or with a b-lactam (FQ  BL).
METHODS: We analyzed a prospective observational cohort of patients with CAP admitted to
the Hospital Clinic of Barcelona between 1996 and 2016. We included only patients with
known microbial cause.
RESULTS: Of 1,715 patients (29%) with known etiology, a total of 932 patients (54%) received
BL þM. Despite lower crude mortality in the BL þM group in the overall population (BL þ
M, 5% vs FQ  BL, 8%; P ¼ .015), after adjustment by a propensity score and baseline
characteristics, the combination of BL þ M had a protective effect on mortality only in
patients with high inﬂammatory response (C-reactive protein, > 15 mg/dL) and pneumo-
coccal CAP (adjusted OR, 0.28; 95% CI, 0.09-0.93). No beneﬁts on mortality were observed
for the population without high inﬂammatory response and pneumococcal CAP or with
other etiologies.
CONCLUSIONS: The combination of a b-lactam with a macrolide was associated with
decreased mortality in patients with pneumococcal CAP and in patients with high systemic
inﬂammatory response. When both factors occurred together, BL þ M was protective for
mortality in the multivariate analysis. CHEST 2019; -(-):---100
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187Community-acquired pneumonia (CAP) is a major
cause of death worldwide.1 The mortality attributed to
CAP is high, despite adequate and early empiric
antimicrobial treatment.2 Empiric antibiotics must cover
the main pathogens that cause pneumonia. Guidelines
suggest the use of a b-lactam plus a macrolide (BL þM),
or a b-lactam plus a ﬂuoroquinolone or a
ﬂuoroquinolone alone (FQ  BL), as empiric treatment
for hospitalized patients, but with ﬂuoroquinolone
monotherapy restricted to non-ICU patients.3-5
Few randomized clinical trials (RCTs) have compared
these antibiotic regimens, and the data available are the
result of retrospective observational analyses.6-17 In
many of these studies, combinations of a BL þ M
showed better results than b-lactam monotherapy, even
in patients with higher severity disease or when the
responsible pathogen is resistant to macrolides. These
beneﬁts have been attributed to the immunomodulatory
effect of macrolides in addition to their antimicrobial
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FLA 5.5.0 DTD  CHEST2049_proof  26 Dimmunomodulatory effect and a similar antimicrobial
spectrum for usual etiologic pathogens of CAP.20
Pneumococcal pneumonia usually has a higher
inﬂammatory response than pneumonia caused by other
organisms, with some exceptions such as Legionella
pneumophila21 and toxin-producing Staphylococcus
aureus. Therefore, we might expect a greater beneﬁcial
effect of including a macrolide in pneumococcal CAP
compared with other etiologic groups. Indeed, several
studies have shown the beneﬁts of including macrolides
in the treatment of pneumococcal CAP compared with
monotherapy, particularly in the presence of
bacteremia.13,22-24
The hypothesis of this study was that combining a
b-lactam with a macrolide in patients with CAP resulted
in decreased 30-day mortality, when compared with a
quinolone-based regimen. We also aimed to test whether
stratifying patients according to microbial etiology of
CAP and the level of systemic inﬂammation was related
to this beneﬁt in mortality.188
189
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201Methods
Study Design and Patients
We performed an observational study on a prospective cohort of
consecutive patients with CAP who were admitted to the Hospital
Clinic of Barcelona (January 1996 to December 2016).
Inclusion criteria were as follows: (1) adults $ 18 years old at
diagnosis; (2) CAP conﬁrmed by chest radiograph and consistent
clinical manifestations (eg, fever, cough, sputum production, pleuritic
chest pain); (3) patients with known etiology; and (4) patients who
received a BL þ M or FQ  BL as empiric treatment.
Exclusion criteria were as follows: (1) previous hospital admission
for $ 48 hours in the preceding 14 days; (2) absence of completeQ8
202
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208
209
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214
215
216
217
218
219
220clinical follow-up for 4 to 6 weeks; (3) severe immunosuppression, as
in transplantation, HIV coinfection, or in patients receiving
chemotherapy or other immunosuppressive drugs (> 20 mg of
prednisone-equivalent per day for 2 weeks or more); and (4) empiric
treatment with combinations other than those described above.
Ethics Statement
The Ethics Committee of the Hospital Clinic of Barcelona approved
the study for the purpose of publication (Register: 2009/5451). The
need for written informed consent was waived because of the
noninterventional design. Patients’ identity remained anonymous.
Data Collection
The comorbidities were recorded from the medical records. Clinical,
laboratory, and radiographic characteristics were recorded on
admission (described in detail in the online article). During
hospitalization, the following data were recorded: length of stay,
admission to the ICU, need for mechanical ventilation (invasive or
noninvasive), and 30-day mortality.
Severe CAP was deﬁned according to American Thoracic Society/
Infectious Diseases Society of America guidelines.3 Pneumonia
Severity Index (PSI),25 Sequential (previously, Sepsis-Related) Organ
Failure Assessment (SOFA),26 and CURB-6527 scores were used to
stratify cases according to severity.
Microbiologic Evaluation
Microbiologic examination is described in detail in the online article.
Deﬁnitions
We separated the patients according to initial antimicrobial treatment
into two groups: patients who received a BL þ M, and patients who
received an FQ  BL.
We also grouped them according to etiology into three groups: patients
with pneumococcal etiology, patients with atypical pathogen etiology
(Chlamydophila pneumoniae, Chlamydia psittaci, Coxiella burnetii,[ -#- CHE ST - 2 0 1 9 ]
ecember 2018  8:15 pm  EO: CHEST-18-2078
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297Mycoplasma pneumoniae, and Legionella pneumophila) and patients
with other etiology (organisms not included in previous groups, or
polymicrobial etiology).
We deﬁned patients with a high inﬂammatory response as those with a
C-reactive protein (CRP) level greater than 15 mg/dL at admission,
based on the results of a previous study.28
Appropriateness of empiric antimicrobial treatment in patients was
deﬁned when the isolated pathogens were susceptible in vitro to one
or more of the antimicrobials administered.
Outcomes
The main outcome was 30-day all-cause mortality.
Statistical Analysis
We report the number and percentage of patients for categorical
variables, the median and interquartile range (IQR) for continuous
variables with a nonnormal distribution, and the mean and standard
deviation for those with a normal distribution. Categorical variables
were compared using the c2 test or the Fisher exact test. Continuous
variables were compared using the t test or the nonparametric
Mann-Whitney test.
Logistic regression analyses29 were used to examine the associations
between 30-day mortality and risk factors. In the ﬁrst step, each risk
factor was tested individually. In the second step, all risk factors that
showed an association in the univariate model (P < .10) were added6,442 screened 
with CAP
1,715 (28%) pa
analyzed
β-lactam plus a fluoroquinolone
or a fluoroquinolone alone
n = 783 (46%)
Pneumococcal
aetiology n = 346
(44%)
Atypical pathogen
aetiology n = 91
(12%)
Others pathogen
aetiology n = 346
(44%)
P
ae
Figure 1 – Flowchart. CAP ¼ community-acquired pneumonia.
chestjournal.org
FLA 5.5.0 DTD  CHEST2049_proof  26 Deceminto the multivariable model. Finally, a backward stepwise selection
(Pin < .05, Pout > .10) was used to determine factors associated with
30-day mortality. If two independent variables were highly correlated
(r > j 0.30j Q), the variable with the largest variance was excluded
from the multivariable analyses.30 The OR and 95% CI were calculated.
A propensity score for patients receiving antimicrobial treatment was
developed31 because the antimicrobial treatment was not randomly
administered to these patients, resulting in a potential confounding
factor and selection bias. The propensity score was determined,
irrespective of the outcome, through a multinomial logistic
regression to predict the inﬂuence of 18 predetermined variables on
the use of antimicrobial treatment. Variables were chosen for
inclusion in the propensity score calculation according to the
methods of Brookhart et al32 and included variables associated with
antimicrobial use and outcome. The score was ﬁnally entered as a
continuous variable in the multivariable logistic regression analysis
for 30-day mortality, together with the antimicrobial treatment, the
microbial etiology, the year of occurrence of pneumonia, and
admission to the ICU. As sensitivity analyses, the same analyses were
performed on the subset of patients with pneumococcal CAP, and
for patients with CRP > 15 mg/dL.
We used the multiple imputation method33 for missing data in the
multivariable analyses. The level of signiﬁcance was set at .05 (two-
tailed). All analyses were performed with SPSS Statistics version 23.0
(IBM, Armonk, NY).298
299
300
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306Results
Patient Characteristics
Of the 6,442 patients with CAP admitted during
the study period, 1,715 (28%) were included in
the present study; the main exclusion
criterion was unknown etiology in 3,840 patients (60%)(Fig 1). Nine hundred and thirty-two patients (54%)
received empiric antibiotic treatment with a BL þM, and
783 patients (46%) received an FQ  BL.
The baseline characteristics of the two groups are
summarized in Table 1. Patients who received a BL þM
had more frequent chronic pulmonary disease and werepatients
tients
Excluded (n = 4,727)
• Unknown aetiology n = 3,841 (60%)
• TB aetiology n = 19 (0,3%)
• HIV coinfections n = 273 (5%)
• Missing in antibiotic treatment n = 284
   (5%)
• Antibiotic treatment other than
   combinations analyzed n = 1,323 (20%)
• Outpatients n = 814 (13%)
β-lactam plus a macrolide
n = 932 (54%)
neumococcal
tiology n = 415
(45%)
Atypical pathogen
aetiology n = 121
(13%)
Others pathogen
aetiology n = 396
(42%)
Q
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TABLE 1 ] Baseline Characteristics of Patients Q21
Variable
b-Lactam Plus
Macrolide (n ¼ 932)
b-Lactam Plus Fluoroquinolone or
Fluoroquinolone Alone (n ¼ 783) P Value
Age, median (IQR), y 72 (57-80) 71 (55-80) .512
Elderly (> 65 y old), No. (%) 607 (65) 475 (61) .057
Male sex, No. (%) 602 (65) 475 (61) .094
Pneumococcal vaccine, No. (%) 94 (16) 133 (19) .195
Inﬂuenza vaccine, No. (%) 225 (38) 316 (45) .016
Chronic pulmonary disease, No. (%) 469 (51) 322 (42) < .001
Heart failure, No. (%) 122 (13) 107 (14) .722
Chronic renal failure, No. (%) 65 (7) 48 (6) .486
Hepatic disease, No. (%) 67 (7) 41 (5) .102
Diabetes mellitus, No. (%) 178 (19) 164 (21) .301
Neurologic disease, No. (%) 104 (11) 110 (15) .045
Former or current smoker, No. (%) 591 (63) 458 (58) .043
Alcohol consumption, No. (%) 160 (17) 125 (16) .474
Nursing home, No. (%) 21 (3) 51 (7) < .001
Previous antibiotic therapy, No. (%) 164 (18) 176 (24) .004
Systemic steroids, No. (%) 27 (4) 48 (6) .088
Inappropriate treatment, No. (%) 23 (5) 19 (5) .697
Creatinine, median (IQR), mg/dL 1.1 (0.9-1.5) 1.1 (0.9-1.6) .285
C-reactive protein, median (IQR), mg/dL 22 (11-29) 22 (12-30) .169
White blood cell count, median (IQR),  109/L 13.8 (8.9-18.6) 13.1 (9-18.3) .581
PaO2/FIO2, median (IQR), mm Hg 281 (238-314) 271 (229-314) .072
Percentages calculated on nonmissing data. Boldface entries indicate statistical signiﬁcance. IQR ¼ interquartile range.
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440more often former or current smokers; they had less
frequent neurologic disease, previous inﬂuenza
vaccination, nursing home residence, or previous
antibiotic therapy.
The main causal organism was Streptococcus
pneumoniae in both groups (Fig 1). Detailed
information on microbial etiology is shown in Table 2.
High inﬂammatory response (CRP > 15 mg/dL) at
admission was present in 534 patients (70%) with
pneumococcal CAP, 117 patients (55%) with atypical
etiology, and 341 patients (46%) with another etiology.
We found no differences in severity scores such as
CURB-65, PSI, or SOFA; however, patients who received
an FQ  BL were more frequently admitted to the ICU,
and more often required noninvasive ventilation, or
presented with severe CAP, particularly septic shock. No
differences were observed in the requirement for
invasive mechanical ventilation (Table 3).
Antibiotic Treatment
Among 1,715 patients, 1,387 (81%) were treated with a
b-lactam; of these, 1,209 (87%) received ceftriaxone.4 Original Research
FLA 5.5.0 DTD  CHEST2049_proof  26 DPatients treated with a BL þM received azithromycin in
758 cases (81%), erythromycin in 111 cases (12%), and
clarithromycin in 63 cases (7%).
In patients treated with an FQ  BL, 455 (58%) received
a ﬂuoroquinolone in combination with a b-lactam. In
this group 767 patients (98%) received levoﬂoxacin, 12
patients (1.5%) received ciproﬂoxacin, and 4 patients
(0.5%) received moxiﬂoxacin; all patients given
ciproﬂoxacin received that treatment in combination
with a b-lactam.
Outcomes
Patients receiving a BL þ M had lower crude 30-day
mortality compared with patients who received an FQ
 BL (5% vs 8%; P ¼ .015) (Table 4). Similar results
were observed in patients with a high inﬂammatory
response (BL þM, 3% vs FQ  BL, 8%; P < .001) and
for patients with pneumococcal CAP (BL þ M,
4% vs FQ  BL, 9%; P ¼ .004). The greatest
difference in mortality was observed in patients with
both a high inﬂammatory response and pneumococcal
CAP (BL þ M, 2% vs FQ  BL, 10%; P # .001). No[ -#- CHE ST - 2 0 1 9 ]
ecember 2018  8:15 pm  EO: CHEST-18-2078
Q22
TABLE 2 ] Microbial Etiology of Pneumonia
Pathogen
b-Lactam Plus Macrolide
(n ¼ 932) (%)
b-Lactam Plus Fluoroquinolone or
Fluoroquinolone Alone (n ¼ 783) (%)
Pneumococcal pneumonia 415 (45) 346 (44)
Invasive pneumococcal pneumonia 185 (20) 145 (19)
Atypical bacteria 121 (13) 91 (12)
Legionella pneumophila 68 (7) 51 (7)
Chlamydophila pneumoniae 21 (2) 12 (2)
Mycoplasma pneumoniae 21 (2) 20 (3)
Other etiologies 396 (43) 316 (44)
Haemophilus inﬂuenzae 50 (5) 22 (3)
Klebsiella pneumoniae 3 (0.5) 9 (1)
Escherichia coli 11 (1.5) 6 (1)
Pseudomonas aeruginosa 34 (4) 17 (2)
Staphylococcus aureus 19 (3) 15 (2)
Respiratory virus 102 (11) 152 (19)
Moraxella catarrhalis 0 (0) 5 (1)
Polymicrobial 148 (16) 91 (12)
Percentages calculated on nonmissing data.
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522differences in 30-day mortality between both groups
were observed in patients with atypical or other
etiologies. Moreover, we grouped all patients withoutTABLE 3 ] Severity Scores, Site of Care, and Main Complic
Variable
b-Lac
Macrolid
CURB-65 risk classes 3-5, No. (%) 174 (
PSI score, median (IQR) 98 (
PSI risk classes IV and V, No. (%) 428 (
SOFA score, median (IQR) 2 (
Site of care, No. (%)
General ward 759 (
ICU 171 (
Length of hospital stay, median (IQR), d 7 (
Severe CAP, No. (%) 187 (
Noninvasive mechanical ventilation, No. (%) 17 (
Invasive mechanical ventilation,a No. (%) 63 (
Septic shock, No. (%) 69 (
Severe CAP non admitted to ICU
Major criteria, No. (%) 3 (
$ 3 minor criteria, No. (%) 70 (
Major criteria and $ 3 minor criteria, No. (%) 7 (
Percentages calculated on nonmissing data. Boldface entries indicate statistic
Society/Infectious Diseases Society of America criteria.3 CURB-65 ¼ confusion,
Pneumonia Severity Index; SOFA ¼ Sequential Organ Failure Assessment.
aPatients who initially received noninvasive ventilation but subsequently needed
chestjournal.org
FLA 5.5.0 DTD  CHEST2049_proof  26 Decempneumococcal CAP and without a high inﬂammatory
response and again no signiﬁcant differences were
observed.ations
tam Plus
e (n ¼ 932)
b-Lactam Plus Fluoroquinolone
or Fluoroquinolone
Alone (n ¼ 783) P Value
20) 157 (22) .390
76-121) 101 (77-124) .245
57) 340 (60) .365
2-3) 2 (1-3) .762
< .001
82) 561 (72)
18) 221 (28)
5-11) 8 (6-13) < .001
27) 227 (35) .001
2) 47 (7) < .001
7) 65 (9) .176
7) 96 (12) .001
9) 4 (11) .72
58) 78 (73) .021
10) 4 (9) .91
al signiﬁcance. Severe CAP was deﬁned according to American Thoracic
blood urea nitrogen, respiratory rate, blood pressure, age > 65 y; PSI ¼
intubation were included in the invasive mechanical ventilation group.
5
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TABLE 4 ] Crude 30-Day Mortality in Overall Population and Subpopulations Q23
b-Lactam Plus
Macrolide
b-Lactam Plus
Fluoroquinolone or
Fluoroquinolone Alone P Value
Overall population n ¼ 932 n ¼ 783
30-day mortality, No. (%) 45 (5) 60 (8) .015
Pneumococcal pneumonia n ¼ 415 n ¼ 345
30-day mortality, No. (%) 17 (4) 32 (9) .004
High inﬂammatory response (CRP > 15 mg/dL) n ¼ 398 n ¼ 481
30-day mortality, No. (%) 11 (3) 40 (8) < .001
Pneumococcal pneumonia and high inﬂammatory response n ¼ 178 n¼ 239
30-day mortality, No. (%) 3 (2) 25 (10) < .001
Pneumococcal pneumonia without high inﬂammatory
response
n ¼ 94 n ¼ 78
30-day mortality, No. (%) 7 (7) 6 (8) .95
Patients without pneumococcal pneumonia and high
inﬂammatory response
n ¼ 220 n ¼ 242
30-day mortality, No. (%) 8 (4) 15 (6) .21
Atypical pathogens and without high inﬂammatory response n ¼ 25 n ¼ 14
30-day mortality, No. (%) 0 (0) 0 (0) .
Atypical pathogens and high inﬂammatory response n ¼ 55 n ¼ 63
30-day mortality, No. (%) 0 (0) 1 (2) > .999
Other pathogens and without high inﬂammatory response n ¼ 97 n ¼ 125
30-day mortality, No. (%) 6 (6) 9 (7) .77
Other pathogens and high inﬂammatory response n ¼ 165 n ¼ 179
30-day mortality, No. (%) 8 (5) 14 (8) .26
High inﬂammatory response was deﬁned as CRP > 15 mg/dL. Boldface entries indicate statistical signiﬁcance. CRP ¼ C-reactive protein.
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660In the overall population and speciﬁcally in patients with
pneumococcal pneumonia, the propensity-adjusted
multivariable analysis did not show any signiﬁcant
association between the antibiotic treatment and 30-day
mortality (e-Tables 1, 2; e-Fig 1); however, for the
population with a high inﬂammatory response we
observed a signiﬁcant interaction between antimicrobial
treatment and etiology, speciﬁcally for patients with
pneumococcal CAP, who also received antibiotic
treatment with a BL þ M (adjusted OR, 0.28; 95% CI,
0.09-0.92; P ¼ .036) (Table 5). The multivariable
analysis adjusted by propensity score for 30-day
mortality also showed that PSI risk classes IV and V,
acute respiratory distress syndrome, septic shock, and
inappropriate treatment were independent risk factors
for death. The area under the receiver-operating
characteristic curve was 0.85 (95% CI, 0.80-0.89) (e-Fig
1) for the model of 30-day mortality.
Internal validation of the logistic regression model for
patients with high inﬂammatory response was
conducted by bootstrapping with 1,000 samples6 Original Research
FLA 5.5.0 DTD  CHEST2049_proof  26 D(e-Table 3). All variables included in the model
demonstrated robust results, with low 95% CIs around
the original coefﬁcients.
Discussion
In this well-characterized cohort of patients with CAP
we compared the effect of two types of empiric antibiotic
treatments, BL þ M and FQ  BL, on 30-day mortality.
After adjusting for confounders, BL þM did not protect
for mortality in the overall population; however, our
analyses revealed that the combination of a BL þ M
compared with an FQ  BL had an independent
association with less 30-day mortality only in patients
with pneumococcal CAP and in those with a high
inﬂammatory response (CRP > 15 mg/L), with the
greatest beneﬁt in those with both factors present. No
differences in mortality were observed between groups
of patients with other microbial etiologies and high
inﬂammatory response.
Several observational studies have shown that the
combination of a b-lactam with a macrolide is better[ -#- CHE ST - 2 0 1 9 ]
ecember 2018  8:15 pm  EO: CHEST-18-2078
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TABLE 5 ] Signiﬁcant Univariate and Multivariable Logistic Regression Analyses for 30-Day Mortality: Patients With
High Inﬂammatory Response
Variable
Univariate Multivariablea,b
OR 95% CI P Value OR 95% CI P Value
Interaction treatment and etiology .062 .11
b-Lactam plus a macrolide and
Streptococcus pneumoniae
0.27 0.09-0.80 .019 0.28 0.09-0.92 .036
b-Lactam plus a macrolide and
Atypical bacterial
0.44 0.04-5.53 .52 0.59 0.04-7.83 .69
b-Lactam plus macrolide treatment 0.97 0.46-2.03 .93 1.32 0.58-3.00 .50
Etiology .11 .27
Streptococcus pneumoniae 1.52 0.77-2.98 .23 1.36 0.64-2.88 .42
Atypical bacterial etiology 0.36 0.08-1.64 .19 0.41 0.09-1.98 .27
Other etiology 1 ... ... 1 ... ...
Admission after Year 2007 1.47 0.90-2.42 .13 1.06 0.45-2.48 .89
ICU admission 6.65 3.93-11.23 < .001 1.93 0.89-4.20 .096
Elderly (> 65 y old) 2.32 1.29-4.18 .005 ... ... ...
PSI IV and V 5.96 2.82-12.60 < .001 3.97 1.81-8.71 .001
ARDS 6.80 3.61-12.80 < .001 2.63 1.24-5.61 .012
Acute renal failure 5.99 3.46-10.35 < .001 ... ... ...
Septic shock 10.75 6.31-18.30 < .001 4.17 2.05-8.45 < .001
Adequate antibiotic treatment 0.17 0.07-0.42 < .001 0.34 0.12-0.95 .040
Boldface entries indicate statistical signiﬁcance. PSI ¼ Pneumonia Severity Index.
aAdjusted by propensity score.
bHosmer-Lemeshow goodness-of-ﬁt test P ¼ .88.
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770than a b-lactam alone. Therefore, clinical guidelines
suggest the use of a combination of a b-lactam with a
macrolide or a ﬂuoroquinolone, or a ﬂuoroquinolone
alone, for patients with CAP (but ﬂuoroquinolone
monotherapy only for patients with nonsevere CAP).
The beneﬁcial effect of a BL þ M over a combination of
a b-lactam with a ﬂuoroquinolone or a ﬂuoroquinolone
alone is less clear. In this study we compared these
combinations in various subgroups and found
differences in favor of the macrolide combination in a
speciﬁc group of patients. Beneﬁts in pneumococcal
bacteremic CAP were previously reported for a BL þ M
combination even though, when compared with
ﬂuoroquinolone-based therapies, no beneﬁts were
observed13; however, this study did not look at the
inﬂammatory status. A recent study has shown better
outcomes in patients who received macrolide therapy
and presented with bacteremic pneumonia.34 Moreover,
the most common cause of bacteremic pneumonia was
pneumococcus in 74% of patients, and although the
authors did not look at CRP levels, patients with invasive
pneumococcal CAP usually presented greater levels of
CRP.35 A recent meta-analysis that compared the
combination of a b-lactam with a macrolide vs achestjournal.org
FLA 5.5.0 DTD  CHEST2049_proof  26 Decemb-lactam with a ﬂuoroquinolone showed no signiﬁcant
differences in short-term mortality (adjusted risk ratio,
1.26; 95% CI, 0.95-1.67; I2, 43%)36; and another meta-
analysis showed that ceftriaxone combination therapy
was similar in terms of treatment success compared with
ﬂuoroquinolone monotherapy in patients with CAP.37
The study by Postma et al6 was a cluster-randomized
clinical trial that showed that a b-lactam was not inferior
to a combination of a b-lactam with a macrolide or a
ﬂuoroquinolone alone for patients with nonsevere CAP;
however, this study had several methodologic limitations
that made the conclusions not generalized Q. A recent
post-hoc analysis of a multicenter cohort in Japan
evaluated the role of CRP in patients treated with a
b-lactam compared with a combination b-lactam plus
macrolide, showing mortality beneﬁt regardless of
whether the CRP level was above or below 15mg/dL.38
CRP is an inﬂammatory marker that can predict poor
outcomes and treatment failure in patients with CAP or
sepsis for other causes Q, and could be used for evaluate
response to treatment.39-41 As in previous studies on
adjuvant treatments in CAP,28,42 we looked at speciﬁc
populations in whom a BL þ M could have a beneﬁcial
effect. Furthermore, a recent report by the US National7
ber 2018  8:15 pm  EO: CHEST-18-2078
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856Heart, Lung, and Blood Institute43 recognized severe
pneumonia with high inﬂammatory response as an
endotype, and proposed that its presence might be used
to guide therapy.
Macrolides and ﬂuoroquinolones have
immunomodulatory activity. Both act by reducing the
levels of proinﬂammatory cytokines and increasing the
levels of antiinﬂammatory cytokines in in vitro and
in vivo models.20,44,45 The ﬂuoroquinolones have effects
on intracellular cyclic AMP and phosphodiesterases, and
on transcription factors such as NF-kB, activator protein
1.44 Macrolides have effects on structural cells of the
respiratory tract such as endothelial and epithelial cells,
mainly on the expression of adhesion molecules,
reducing the adherence of pneumococci to the
respiratory epithelium.18,19,46,47 A potential explanation
of the impact on pneumococcal CAP with a high
inﬂammatory response is the fact that macrolides not
only inhibit bacterial protein synthesis but are also
potent inhibitors of the production of pneumolysin,
even at subinhibitory concentrations.48,49 The combined
impact on bacteria and on the host response may
explain our ﬁndings.22-24
The main limitation of this study is that it was
performed at a single center, and so the results should
be conﬁrmed in other databases or in prospective
RCTs. Another limitation is that we observed that
patients who received ﬂuoroquinolones alone or in8 Original Research
FLA 5.5.0 DTD  CHEST2049_proof  26 Dcombinations had more severe disease and were
admitted to the ICU more frequently; this may
represent a bias in our study, given that physicians,
including the ICU team, more often used
ﬂuoroquinolones in patients with more severe disease.
We tried to address this issue by adjusting all the
multivariable analyses by ICU admission. In addition,
the etiology of CAP identiﬁed in our study showed a
high frequency of pneumococcal infection, a ﬁnding
that is at variance with the data in a large study from
the United States.50 Our results suggest the need for a
new RCT in a population with S. pneumoniae and
high inﬂammatory response to evaluate the mortality
beneﬁt of adding a macrolide to a b-lactam. The
strengths of our study are that we analyzed a large
database with a well-characterized population with
microbiologic data. In addition, we compared
combinations of a b-lactam with either a macrolide or
a ﬂuoroquinolone; both regimens are active against
the most common pathogens causing CAP, and both
macrolides and ﬂuoroquinolones have
immunomodulatory activity.
In conclusion, the combination of a b-lactam with a
macrolide was associated with decreased mortality in
patients with pneumococcal CAP and in patients with
high systemic inﬂammatory response. When both
factors occurred together, BL þ M combinations were
protective for mortality in the multivariate analysis.857
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